To Exam the Effects of Phyllanthus Niruri Extracts on Human Neutrophils
1 other identifier
observational
240
1 country
1
Brief Summary
To exam the effects of Phyllanthus niruri extracts(corilagin, phyllanthin and brevifolin) on human neutrophils
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
January 23, 2022
CompletedFirst Posted
Study publicly available on registry
January 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2023
CompletedSeptember 1, 2023
January 1, 2022
9 months
January 23, 2022
August 31, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Measurement of superoxide anion release
Superoxide anion released from human neutrophils were determined by measuring ferricytochrome c reduction.The neutrophils were activated with fMLF (30 nM) and cytochalasin B(0.5 μg/mL) (fMLF/CB). Changes in absorbance that occurred at 550 nm were observed continuously using a double beam spectrophotometer. Superoxide anion level was calculated using the methods described in previous report.
After neutrophil isolation, an average of 3 months
Measurement of intracellular ROS formation
Neutrophil ROS production was determined from the conversion of non-fluorescent DHR 123 to fluorescent rhodamine 123, detected using flow cytometry. Neutrophils (2 × 106 cells/ml) were incubated with DHR 123 (2 μM) for 15 min at 37°C, and then treated with honokiol (0.1-10 μM) for 5 min before the addition of fMLP/CB (0.5 μg/ml) for a further 5 min. The change in fluorescence was analysed using flow cytometry
After neutrophil isolation, an average of 3 months
Interventions
Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
Eligibility Criteria
Voluntary healthy donor (20-35 years old) do not have coagulopathy, systemic infective disease and severe liver and renal function impairment.
You may qualify if:
- Healthy volunteers who aged 20-35 years.
- Do not have coagulopathy, systemic infection disease and severe liver and renal function impairment
- Accept venipuncture
You may not qualify if:
- Healthy volunteers who aged over 35 years.
- Have coagulopathy, systemic infection disease and severe liver and renal function impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chang Gung Memorial Hospital
Taoyuan District, 333, Taiwan
Biospecimen
Seperation of human neutrophils were according to a standardized procedures and following steps: using 3%(w/v) dextran sedimentation for 30 min, then gradient centrifugation in Ficoll-Hypaque, and hypotonic lysis of erythrocytes. The purified neutrophils were determined by the Trypan blue exclusion method and need to contained \>98% viable cells. Then they were suspended in without calcium ion HBSS buffer (pH 7.4), and stored at 4 °C for analysis
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 23, 2022
First Posted
January 25, 2022
Study Start
January 1, 2022
Primary Completion
September 30, 2022
Study Completion
July 31, 2023
Last Updated
September 1, 2023
Record last verified: 2022-01